JILIN AODONG(SZ:000623) Sou Hu Cai Jing·2025-08-01 14:15Core Insights - Jilin Aodong reported a closing price of 19.04 yuan as of August 1, 2025, with a slight increase of 0.42% and a turnover rate of 1.65% [1] - The company experienced a significant net outflow of main funds amounting to 33.51 million yuan, representing 8.9% of the total transaction amount [1] - The latest quarterly report shows total revenue of 623 million yuan, a year-on-year decrease of 27.71%, while net profit attributable to shareholders reached 517 million yuan, a year-on-year increase of 259.75% [1] Financial Performance - Total revenue for Q1 2025 was 623 million yuan, down 27.71% year-on-year [1] - Net profit attributable to shareholders was 517 million yuan, up 259.75% year-on-year [1] - Non-recurring net profit was 488 million yuan, reflecting a year-on-year increase of 75.56% [1] - Current ratio stands at 1.871, quick ratio at 1.525, and debt-to-asset ratio at 11.43% [1] Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. was established in 1993 and is located in Yanbian Korean Autonomous Prefecture [2] - The company primarily engages in the pharmaceutical manufacturing industry [2] - The registered capital of the company is approximately 11.96 billion yuan, with the same amount in paid-in capital [1][2] Investment and Intellectual Property - Jilin Aodong has invested in 47 external enterprises and participated in one bidding project [2] - The company holds 216 trademark registrations and 8 patents, along with 3 administrative licenses [2]